A PHASE 1/2 MULTICENTER OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF CC-122 IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
Brief description of study
If you have been diagnosed with unresectable hepatocellular carcinoma (liver cancer), you may qualify to participate in a study evaluating the safety, tolerability and preliminary efficacy of the drug CC-122 in combination with nivolumab. The main goal of this phase I/II is to see whether the drug CC-122 in combination with nivolumab is effective in treating patients who have unresectable liver cancer. In addition, we would like to study blood samples to understand how much CC-122 in combination with nivolumab is in the blood over time, which is known as pharmacokinetic (PK) testing.
Clinical Study Identifier: s16-01478
ClinicalTrials.gov Identifier: NCTs16-01478
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
